Malaria remains a global health crisis, with inadequate adherence to current treatments, growing drug resistance, and devastating fatalities highlighting the urgent need for innovation. Amaterasu Lifesciences in collaboration with ICT is proud to introduce our patented solution: a revolutionary single-dose anti-malarial injection (SiDMI) designed to transform malaria treatment worldwide.

The Challenge of Malaria
Traditional multi-dose oral and injection therapies for malaria often face challenges with patient non-adherence, leading to incomplete treatment and increased risk of drug resistance. This, in turn, contributes to the ongoing burden of malaria, particularly in vulnerable populations.Currently the available injectable therapy comprises only artemisinin as mono-therapy and mono therapy is not recommended by WHO, hence there is an unmet need for an injectable dosage form with combination ACT as recommended by WHO.

Our Patented Solution: SiDMI
Amaterasu Lifesciences’ SiDMI is a game-changer in malaria treatment. By combining Artemether and Lumefantrine in a single-dose injection, we address the issue of non-adherence head-on. Our advanced drug delivery technology ensures effective treatment with a single administration, reducing the risk of drug resistance and improving patient outcomes.

SiDMI: A First-of-Its-Kind
SiDMI is the world’s first single-dose injectable treatment for malaria. This groundbreaking approach has the potential to revolutionize how malaria is managed globally. Rigorous pre-clinical efficacy and PK studies, along with comprehensive pharmacodynamic studies, have demonstrated the safety and effectiveness of SiDMI. We are now preparing for IND submission, marking a significant step towards making this life-saving treatment a reality.
With SiDMI, Amaterasu Lifesciences is leading the fight against malaria. We are confident that this single-dose injection will not only save lives but also redefine the landscape of malaria treatment on a global scale.